Movectro: Withdrawal of the marketing authorisation application
Table of contents
On 8 February 2011, Merck Serono Europe Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Movectro, for the treatment of relapsing-remitting multiple sclerosis.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Movectro (PDF/997.77 KB)Adopted
First published: 30/03/2011
Last updated: 30/03/2011
Movectro: Withdrawal letter (PDF/1.9 MB)
First published: 23/02/2011
Last updated: 23/02/2011
Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine) (PDF/49.46 KB)
First published: 17/02/2011
Last updated: 17/02/2011
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').